As FDA's Peter Marks resigns, industry watchers size up vaccine, cell and gene therapy hits
As the FDA wavers from cuts, changes and departures under the second Trump administration, another vital figure of the agency is heading for the exit. | In resigning as director of the FDA’s Center for Biologics Evaluation and Research,
Peter Marks’ ouster comes at a time when the sector is already suffering through a years-long public markets slump.
Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.
The stock market—and biotech insiders—reacted negatively to the allegedly forced resignation of CBER Director Peter Marks, ...
Pluvicto, Novartis’ blockbuster radiopharmaceutical for prostate cancer, has been greenlighted by the FDA for use earlier in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback